News UK budget includes £1bn biopharma investment package UK Chancellor John Healey's first Budget speech included a £1bn-plus industry investment package at sites in Manchester, Oxford, and Loughborough.
News Astellas pays $285m for Audax cancer drug, and other deals Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.
News GSK shares come under pressure from weaker vaccine sales Shares in GSK fell on a decline in vaccine sales in Q3, although demand for other drugs was strong with signs that its revamp is starting to deliver.
News Lilly's triple G overpowers Ozempic in diabetes trial Eli Lilly has added another arrow to the quiver of new diabetes and obesity drug retatrutide, outperforming Novo's Ozempic in a head-to-head trial.
News AbbVie bids to join the BCMA crowd with etentamig AbbVie has filed for FDA approval of its BCMAxCD3 bispecific etentamig in multiple myeloma, a key pillar of its expansion into oncology.
News US MCT8 deficiency patients get 1st drug as Emcitate debuts Egetis has launched the first-ever therapy for the ultra-rare disease MCT8 deficiency in the US, with a list price of $950,000 per year.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.